DE
DNA icon

DV Equities’s Ginkgo Bioworks DNA Stock Holding History

DV Equities’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.32K Buy
+400
New +$4.31K ﹤0.01% 686

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DV Equities's DNA Position: Q4 2025 in Review

DV Equities opened a new position in Ginkgo Bioworks (DNA) in Q4 2025: 400 shares worth $3.32K. The stake represents ﹤0.01% of the portfolio and ranks #686 among its holdings.

181 funds tracked by Wall St. Rank hold DNA as of Q4 2025.

  • DV Equities held 400 shares of Ginkgo Bioworks worth $3.32K as of Q4 2025.
  • Ginkgo Bioworks was a new DV Equities position in Q4 2025.
  • Ginkgo Bioworks made up ﹤0.01% of DV Equities's portfolio in Q4 2025, its #686 holding.
  • 181 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2025.

Based on DV Equities's 13F filing for Q4 2025, filed 17 Feb 2026.